Cipla’s subsidiary -- Jay Precision Pharmaceuticals has entered into Share Purchase, Subscription and Shareholder’s Agreement (SPSSA) to acquire 26% stake on a fully diluted basis in AMPIN Energy C&I Eighteen, for setting up captive solar power project in Maharashtra. This in line with the commitment to enhance the share of renewable power source in its operation and to comply with regulatory requirement for being a ‘captive user’ under Indian electricity laws.
The total consideration to be paid for the said acquisition is up to Rs 1.46 crore and the subscription to equity shares is expected to be completed within 1 month from the date of the signing of the transaction documents, or by such other date as maybe mutually agreed between the parties. Post transaction, the company’s stake in AMPIN Energy C&I Eighteen would be 26% on a fully diluted basis.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: